MindWalk Holdings (HYFT) EBITDA Margin (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly EBITDA Margin of 77.57% for Q2 2026, down 5330.0% year-over-year from 1.48% in Q2 2025, and down 12874.6% quarter-over-quarter from 0.6% in Q1 2026.
MindWalk Holdings (HYFT) EBITDA Margin (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported EBITDA Margin for 7 consecutive years, with 77.57% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA Margin fell 5330.0% year-over-year to 77.57%; the TTM figure through Apr 2026 stood at 38.97% (up 3180.0% YoY), while the FY2026 annual figure was 20516.78%, up 3302171.0% from the prior year.
- EBITDA Margin retreated to 77.57% in Q2 2026 per HYFT's latest filing, from 0.6% in the prior quarter.
- Across five years, EBITDA Margin topped out at 399.86% in Q2 2023 and bottomed at 197.09% in Q3 2024.
- Historically, EBITDA Margin has averaged 0.64% across 5 years, with a median of 0.15% in 2022.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 2000000000 bps — and 2023, when it jumped 48169 bps.
- MindWalk Holdings' EBITDA Margin stood at 0.0% in 2022, then sank by 30292 bps to 0.05% in 2023, then slumped by 329801 bps to 151.33% in 2024, then jumped by 100 bps to 0.07% in 2025, then plunged by 115179 bps to 77.57% in 2026.
- Business Quant data shows HYFT's EBITDA Margin at 77.57% in Q2 2026, 0.6% in Q1 2026, and 0.07% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -25,380.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -77.57% |
| Jan 31, 2026 | -0.60% |
| Oct 31, 2025 | -0.07% |
| Jul 31, 2025 | 0.00% |
| Apr 30, 2025 | -24.27% |
| Jan 31, 2025 | 0.00% |
| Oct 31, 2024 | -151.33% |
| Jul 31, 2024 | -197.09% |
| Apr 30, 2024 | 287.02% |
| Jan 31, 2024 | -53.69% |
| Oct 31, 2023 | -0.05% |
| Jul 31, 2023 | -0.07% |
| Apr 30, 2023 | 399.86% |
| Jan 31, 2023 | -88.57% |
| Oct 31, 2022 | 0.00% |
| Jul 31, 2022 | -0.21% |
| Apr 30, 2022 | -81.83% |
| Jan 31, 2022 | -0.09% |
| Oct 31, 2021 | -98.59% |
| Jul 31, 2021 | -75.54% |